Delivery Order SPE2DB24D9203-SPE2DB25FXBV9
Award Date
4/30/25
Potential Completion Date
5/1/25
Potential Value
$3.9K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $11,692.95 contract is for the delivery of 4,567,994,749 units of the MENQUADFI VIAL 0.5ML medical product. The contract has an ultimate completion date of April 17, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract, valued at $7,015.77, is for the delivery of MENQUADFI VIAL 0.5ML pharmaceutical products. The contract has an ultimate completion date of April 30, 2025 and does not have a set-aside designation. DMS Pharmaceutical Group Inc. is a pharmaceutical wholesaler that specializes in providing a range of pharmaceutical products, including...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $11,500.30, is for the delivery of MENQUADFI VIAL 0.5ML medical supplies. DMS Pharmaceutical Group holds a larger single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract, valued at $11,692.95, is for the delivery of MENQUADFI VIAL 0.5ML pharmaceutical products. The contract is a firm fixed-price delivery order and does not have a set-aside designation. DMS Pharmaceutical Group Inc. is the prime contractor and holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of a pharmaceutical item, specifically the MENQUADFI VIAL 0.5ML. The order has a completion date of January 10, 2024, and a potential value of $1,169.61. The contract does not have a set-aside designation. DMS Pharmaceutical Group Inc. is a leading pharmaceutical wholesaler that provides a range of brand and generic prescription...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) as a firm fixed-price delivery order valued at $1,559.06. The contract is for the delivery of MENQUADFI VIAL 0.5ML, a specialized pharmaceutical product, with a performance period through February 13, 2025. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
This is a federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract award, valued at $2,338.59, is for the delivery of MENQUADFI VIAL 0.5ML pharmaceutical products. This award is a delivery order under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA, valued at $499,999,999 and valid through November 2026. The IDC allows the DLA to issue firm fixed-price delivery orders for a...
This is a delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA) under the SPE2DB indefinite delivery contract. The order is for 4565902452 MENQUADFI VIAL 0.5ML, with a ceiling value of $3,897.65 and a firm fixed price. The period of performance runs through September 20, 2024. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, providing a wide range of branded...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract, valued at $3,118.12, is for the delivery of 4568025982 MENQUADFI VIAL 0.5ML, a pharmaceutical product. The contract has a firm fixed-price pricing type and an ultimate completion date of April 17, 2025. DMS Pharmaceutical Group Inc. is the prime contractor and does not have any listed subcontractors. The contract is not associated with a...
The Defense Logistics Agency Troop Support Medical awarded a firm fixed price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide MENQUADFI VIAL 0.5ML pharmaceutical supplies. The order, with a potential value of $170,632.31, has a completion date of September 15, 2022. DMS Pharmaceutical Group is a leading pharmaceutical wholesaler that holds various federal contracts and indefinite delivery vehicles to supply pharmaceuticals and medical products to support...